NCT01122004

Brief Summary

The studied patients will be given randomly one of three following drugs1:Gabapentin2: Pregabalin or placebo for 3 days after Photorefractive keratectomy surgery. The pain will be measured based on visual analog scale(VAS) on the day of operation and on the 3 rd day (morning, evening) and then compared among three groups.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 12, 2010

Completed
1 month until next milestone

First Posted

Study publicly available on registry

May 12, 2010

Completed
Last Updated

May 12, 2010

Status Verified

March 1, 2010

First QC Date

April 12, 2010

Last Update Submit

May 10, 2010

Conditions

Outcome Measures

Primary Outcomes (1)

  • pain degree based on visual analog scale(VAS)

Study Arms (2)

Gabapentin

ACTIVE COMPARATOR
Drug: Pregabalin

Pregabalin

ACTIVE COMPARATOR
Drug: Pregabalin

Interventions

Gabapentin

Eligibility Criteria

Age17 Years+
Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • patients candidate for PRK, 17\<age\<70

You may not qualify if:

  • use of any systemic analgesic drugs, drug intolerance, need of systemic or topical administration of NSAIDs or eye drops for allergy and glaucoma, dry eyes, pregnancy, breast feeding

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ophthalmic Research Center

Tehran, Tehran Province, 166666, Iran

RECRUITING

MeSH Terms

Conditions

Refractive Errors

Interventions

Pregabalin

Condition Hierarchy (Ancestors)

Eye Diseases

Intervention Hierarchy (Ancestors)

gamma-Aminobutyric AcidAminobutyratesButyratesAcids, AcyclicCarboxylic AcidsOrganic ChemicalsAmino AcidsAmino Acids, Peptides, and Proteins

Central Study Contacts

Amir faramarzi, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Purpose
TREATMENT
Sponsor Type
OTHER

Study Record Dates

First Submitted

April 12, 2010

First Posted

May 12, 2010

Last Updated

May 12, 2010

Record last verified: 2010-03

Locations